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Abstract
Background: Identifying consistent changes in cellular function that occur in multiple types of
cancer could revolutionize the way cancer is treated. Previous work has produced promising
results such as the identification of p53. Recently drugs that affect serotonin reuptake were shown
to reduce the risk of colon cancer in man. Here, we analyze an ensemble of cancer datasets focusing
on genes involved in the serotonergic pathway. Genechip datasets consisting of cancerous tissue
from human, mouse, rat, or zebrafish were extracted from the GEO database. We first compared
gene expression between cancerous tissues and normal tissues for each type of cancer and then
identified changes that were common to a variety of cancer types.
Results:  Our analysis found that significant downregulation of MAO-A, the enzyme that
metabolizes serotonin, occurred in multiple tissues from humans, rodents, and fish. MAO-A
expression was decreased in 95.4% of human cancer patients and 94.2% of animal cancer cases
compared to the non-cancerous controls.
Conclusion: These are the first findings that identify a single reliable change in so many different
cancers. Future studies should investigate links between MAO-A suppression and the development
of cancer to determine the extent that MAO-A suppression contributes to increased cancer risk.
Background
One of the key goals in cancer research is to identify bio-
logical changes that distinguish normal tissue from can-
cerous tissue. A common approach to identifying
oncogenes has been to assess gene expression in each type
of cancer and compare it to non-cancerous tissue of the
same organ. Comparisons within a single cancer type
(e.g., breast cancer) or class (e.g., leukemia) have yielded
potential oncogenic mechanisms that have been success-
fully used to develop therapeutic strategies for individual
cancer types. For instance, real-time polymerase chain
reaction (qPCR) research has found increased expression
of oncogenes like c-myc [1] and decreased expression of
tumor suppressors like Rb [2]. Western blotting has been
used to show overexpression of functional erb-B2 in
breast cancers [3] and ovarian cancers [4]. Unfortunately,
comparing the data obtained from studies of individual
types of cancer has resulted in only limited success at
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detecting consistent changes among different types of can-
cers. One such success is the identification of a mutation
in p53, a protein responsible for repairing cellular DNA,
which occurs in approximately 50% of all cancers [5]. The
discovery of similarities among various cancer tissues is
the first step in identifying a common mechanism that
contributes to the development of cancer. Once a change
is identified, appropriate therapeutic targets can be devel-
oped to help physicians identify at-risk individuals and
improve patient care. Indeed, novel therapeutic strategies
have been developed as a result of the extensive study of
p53 [6].
Although best known as a neurotransmitter, only 1% of
the tryptophan (Trp) derivative, serotonin (5-HT), is
found in the nervous system. The remaining serotonin is
found in the periphery and is active in the immune, circu-
latory, reproductive, musculoskeletal, and gastrointestinal
systems [7]. Depending on receptor distributions, serot-
onin activity can promote or reduce apoptosis [8]. Our
previous work explored the activity of serotonin in an
array of pathologies, particularly those in which epidemi-
ological data suggests gender differences [7]. We proposed
that estrogenic effects on serotonergic function and recep-
tor distribution could explain gender differences in path-
ologic incidence, as well as some of the effects of estrogen
on breast cancer. Rather than being specific to breast can-
cer, the role of serotonin and its precursor Trp in cellular
physiology suggests that the metabolic pathway of tryp-
tophan and as a result serotonin metabolism may be
involved in the promotion or progression of cancers in
general. There is some literature supporting this hypothe-
sis [9-17], but further research is needed to understand the
exact relationship between Trp or its metabolites and can-
cer. Recently a mechanism was proposed by which catab-
olism of Trp by indoleamine 2,3-dioxygenase can be
linked to immune evasion in tumor cells [13,18]. Other
studies suggest that decreased serum tryptophan levels are
predictive of poorer prognosis and quality of life in cancer
patients[14]. For serotonin specifically, several studies
have shown that the selective serotonin reuptake inhibi-
tors (SSRIs) which prevent the reuptake of serotonin thus
increase extracellular serotonin levels, have anti-cancer
activity in cancer cell lines[17], decrease incidence of can-
cer in both animals [19] and humans [9], and can be used
as a treatment for lymphoma/leukemia [20].
Using genechip technology to study multiple types of can-
cer simultaneously we can identify whether multiple can-
cers have similar gene expression changes [21]. Here, we
analyzed an ensemble of cancer genechip datasets focus-
ing on genes involved in tryptophan metabolism, which
include serotonergic genes among them. We first compare
gene expression between cancerous tissues and normal
tissues for each type of cancer and then identify changes
that are common to a variety of cancer types.
Results
By conducting a series of analyses focusing on tryptophan
related gene expression data (see Table 1 for a list of genes
analyzed) in the GEO database (gene expression omni-
bus) maintained by NCBI [22], we found that only
Monoamine Oxidase A (MAO-A, E.C. 1.4.3.4) showed
consistent decreased expression, in cancers among a vari-
ety of tissues from humans, rodents, and zebrafish. Specif-
ically, only MAO-A expression was significantly altered in
all 13 of the datasets that used non-cancerous patients as
controls and half of the paired datasets. Table 2 provides
specific p-values and the mean fold change in MAO-A for
the datasets analyzed. Although the extent of downregula-
tion varied among patients, cumulatively 95.4% of all of
the tissue samples from human cancer patients, and
94.2% of all animal cancer cases showed lower MAO-A
expression than the single lowest control sample in their
respective dataset. Changes in expression for unpaired
data are provided in Figure 1.
Within each dataset, between 67% to 100% of patients
had MAO-A expression below the lowest control sample
(see Table 2 for individual values). Examining data from
individual patients among the paired data revealed a
remarkable pattern of downregulation in cancerous tissue
among paired samples analyzed. Only a subset of the
datasets that compared cancerous tissue to normal tissue
from the same patient failed to show significant downreg-
ulation. The three datasets that did not contain a signifi-
cant shift in MAO-A expression after correcting for
multiple t-tests were the two papillary thyroid cancer data-
sets and one gastric cancer dataset. However 69% of thy-
roid cancer patients and 100% of gastric cancer patients
exhibited a decrease in expression compared to non-can-
cerous tissue from the same patient, this discordance sug-
gests that a less pronounced downregulation of MAO-A
occurs in patients with these two types of cancer.
Discussion
To our knowledge there has been no previous report of
any genetic mutation or expression change that occurs
with such high frequency among patients in a variety of
cancers. The regularity of this change suggests that low lev-
els of MAO-A might serve as a biomarker for cancer. In
addition, it is possible that the lack of significant differ-
ences in thyroid and gastric cancer could be a result of an
overall decrease in MAO-A levels in both normal and can-
cerous tissue. Unfortunately, datasets that compared can-
cerous thyroid and gastric tissues to those of healthy
individuals were not available at the time of this study.BMC Genomics 2008, 9:134 http://www.biomedcentral.com/1471-2164/9/134
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In higher species there are two isoforms of Monoamine
Oxidase (MAO): MAO-A and MAO-B. In humans MAO-A
preferentially metabolizes serotonin and the dopamine
derivatives epinephrine, and norepinephrine; specifically
MAO-A is responsible for catalyzing the inactivation of
serotonin by removal of a terminal amine group. MAO-B
metabolizes phenethylamine, and both MAO-A and
MAO-B metabolize dopamine. There is a significant
amount of literature regarding the role of dopamine in
carcinogenesis [10,23,24], and several studies have indi-
cated that it may have an antiproliferative effect [25]. The
dopamine derivatives epinephrine and norepinephrine
have also been implicated in carcinogenesis [26,27].
These hormones are released in response to stress and are
also metabolized by MOA-A. Both epinephrine and nore-
pinephrine are capable of increasing cell growth in tumor
cells [28] and drugs that prevent norepinephrine signaling
can reduce cancer risk [29]. In contrast the role of serot-
onin is less clear, while drugs that increase serotonin seem
to have a protective effect in leukemias/lymphoms [20] as
well as other cancers [12], increased serotonin appears to
promote mitosis in vitro [11]. However our findings of a
consistent change in MAO-A, but not MAO-B, in conjunc-
tion with the literature provide some support for our
premise that the critical role of MAO-A in cancer occurs
via the serotonergic system rather than the dopaminergic
or catecholamine system.
MAO-A is the target of monoamine oxidase inhibitors
(MAOIs), a class of antidepressants. There have been sev-
eral epidemiologic studies that examine the risk between
antidepressants and cancer[15,30-32]. While certain stud-
ies link the use of MAOIs with an increase risk for can-
cer[30,32] the literature remains inconclusive about the
exact risk [15,30,32,33]. Given the downregulation of
MAO-A observed in cancerous tissue here, one might
Table 1: Genes listed in the tryptophan pathway in KEGG.
Gene symbol Gene name Gene symbol Gene name
AADAT aminoadipate aminotransferase HEMK1 HemK methyltransferase family member 1
AANAT Arylalkylamine N-acetyltransferase HSD17B10, HADH2 hydroxysteroid (17-beta-dehydrogenase)
ABP1 Amiloride binding protein 1 HSD17B4 hydroxysteroid
ACAT1, ACAT acetyl-Coenzyme A acetyltransferase 1 INDO, IDO indoleamine-pyrrole 2,3 dioxygenase
ACAT2 acetyl-Coenzyme A acetyltransferase 2 INDOL1 indoleamine-pyrrole 2,3 dioxygenase-like 1
ACMSD Aminocarboxymuconate semialdehyde 
decarboxylase
INMT indolethylamine N-methyltransferase
AFMID Arylformamidase KMO Kynurenine 3-monooxygenase
ALDH1A3 Aldehyde dehydrogenase 1 family, member A KYNU kynureninase
ALDH1B1 Aldehyde dehydrogenase 1 family, member B LCMT1 Leucine carboxyl methyltransferase 1
ALDH2 Aldehyde dehydrogenase 2 family LCMT2 Leucine carboxyl methyltransferase 2
ALDH3A1, ALDH3 Aldehyde dehydrogenase 3 family LNX1 ligand of numb-protein X 1
ALDH3A2 Aldehyde dehydrogenase 3 family, member A MAOA monoamine oxidase A
ALDH7A1 Aldehyde dehydrogenase 7 family, member A MAOB monoamine oxidase B
ALDH9A1 Aldehyde dehydrogenase 9 family, member A METTL2B, METTL2 methyltransferase like 2B
AOC2 amine oxidase, copper containing 2 METTL6 methyltransferase like 6
AOC3 amine oxidase, copper containing 3 NFX1 nuclear transcription factor, X-box binding
AOX1 Aldehyde oxidase 1 OGDH oxoglutarate
ASMT acetylserotonin O-methyltransferase OGDHL oxoglutarate dehydrogenase-like
CARM1 Coactivator-associated arginine 
methyltransferase
PRMT2, HRMT1L1 Protein arginine methyltransferase
CAT Catalase PRMT3, HRMT1L3 Protein arginine methyltransferase
CYP1A1, CYP1 Cytochrome P450, family 1, subfamily A PRMT5 Protein arginine methyltransferase 5
CYP1A2 Cytochrome P450, family 1, subfamily A PRMT6, HRMT1L6 Protein arginine methyltransferase
CYP1B1, GLC3A cytochrome P450, family 1, subfamily B PRMT7 Protein arginine methyltransferase 7
DDC dopa decarboxylase PRMT8, HRMT1L3, HRMT1L4 Protein arginine methyltransferase
ECHS1 enoyl Coenzyme A hydratase, short chain, 1, TDO2 Tryptophan 2,3-dioxygenase
EHHADH enoyl-Coenzyme A TPH1, TPRH, TPH Tryptophan hydroxylase 1
GCDH glutaryl-Coenzyme A dehydrogenase TPH2 Tryptophan hydroxylase 2
HAAO 3-hydroxyanthranilate 3,4-dioxygenase WARS, IFI53 tryptophanyl-tRNA synthetase
HADH, HADHSC hydroxyacyl-Coenzyme A dehydrogenase WARS2 tryptophanyl tRNA synthetase 2, 
mitochondrial
HADHA hydroxyacyl-Coenzyme A dehydrogenase WBSCR22 Williams Beuren syndrome chromosome 
region
Genes listed in the tryptophan pathway in KEGG. Each dataset was filtered for the tryptophan related genes and all tryptophan related genes 
included in the dataset were analyzed as described above. The column labeled Gene symbol contains the abbreviated gene symbol. The column 
labeled gene name contains the full gene nameB
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Table 2: Descriptive information on datasets extracted from the GEO database used in this study.
Human Independent Samples (Case-control)
GSE Number GEO Description Species Control (N) Cancer Type (N) Mean Fold Difference in MAO-A p-value Percentage of cancer 
samples < lowest control
GSE3189 Cutaneous malignant melanoma H Normal (7) Malignant Melanoma 
(45)
-15.0 4.9*10-21 100%
GSE1037 Lung neuroendocrine tumor classification H Normal Lung (19) Small Cell lung 
Carcinoma (15)
-9.7 1.1*10-10 100%
GSE2549* Human Malignant Pleural Mesothelioma H Normal Pleura (5) Malignant pleural 
mesothelioma (40)
-7.4 4.6*10-10 90%
GSE61 Breast tumor characterization H Normal Breast (10) Basal-like Tumors (10) -5.6 1.6*10-4 100%
GSE2379 Hypopharyngeal cancer at various stages of progression H Normal Uvula (3) Early Stage (4) -3.4 7.7*10-4 100%
GSE3744 Basal-like breast cancer tumors H Normal Breast (7) Basal-like Cancer (18) -5.7 0.002 88%
* Lung tissue and cell lines were excluded. Only primary tumor samples and normal pleura were analyzed.
Paired Samples
GEO Series 
Number
Cancer Type Species Control (N) Cancer (N) Fold Difference in MAO-A p-value Percentage
GSE3268 Human Squamous Cell Carcinoma of the lung H Control (5) Cancer (5) -2.7 0.001 100%
GSE781 Clear Cell Carcinoma of the human kidney H Normal (7) Renal clear Cell 
Carcinoma (7)
-2.2 0.002 100%
GSE2514 Pulmonary adenocarcinoma H Adjacent Normal (10) Tumor (10) -1.7 0.004 80%
GSE2685** Gastric cancer H Normal (6) Cancer (6) -3.6 0.03§ 100%
GSE3678 Papillary thyroid cancer H Normal (7) Papillary thyroid Cancer 
(7)
-1.2 0.08§ 71%
GSE3467 Papillary thyroid cancer H Normal (9) Papillary thyroid 
Carcinoma (9)
-1.1 0.286§ 67%
**Paired data was extracted and unpaired samples were excluded.
Animal Models
GEO Series 
Number
Cancer Type Species Control (N) Cancer (N) Fold Difference in MAO-A p-value Percentage
GSE2514 Urethane-induced lung tumor model of pulmonary 
adenocarcinoma
M Adjacent Normal (10) Tumor (29) -1.7 6.6*10-10 86%
GSE3519*** Liver cancer model Z Normal Liver Tissue 
(10)
Liver Tumor (10) -2.2 1.7*10-5 100%
GSE3348 LH overexpressing virgin mice (luteinizing hormone 
overexpression causes spontaneous mammary tumors)
M Wild type Breast tissue 
(3)
LH-overexpressing 
Breast tissue (3)
-1.7 5.9*10-5 100%
GSE2426 Patched heterozygous model of medulloblastoma M Granule cell Precursor 
(4)
Tumor Cells from 
Heterozygotes (5)
-1.6 6.9*10-5 100%
GSE422 Colon cancer M C57/BL6 wild-type (6) APC(Min/+) mutant 
(10)
-18.9 1.1*10-4 100%
GSE1872**** N-methyl-N-nitrosourea-induced breast cancer model 
(R)
R Normal (11) Cancer (9) -1.7 5.9*10-5 100%
GSE2528 Mammary tumorigenesis in MMTV-neu model M Wild type Normal 
Breast (3)
Mammary tumors in 
MMTV-neu Model (7)
-1.8 0.001 100%
*** Zebrafish do not have separate MAO-A and MAO-B therefore MAO levels were analyzed.
**** Biological replicates were averaged for the analysis.
Descriptive information on datasets extracted from the GEO database used in this study. Cases are grouped by whether control and cancer tissues came from different human patients (independent samples), the same human 
patients (paired samples), or animal models. Tissues are from humans (H) mice (Mus musculus, M), rats (Rattus norvegicus, R), or zebrafish (Danio rerio, Z). For each dataset, sample sizes of control and cancer tissues are provided. 
The fold difference in mean intensities of MAO-A describes the amount of suppression of the expression of that gene in cancerous tissue; for example, a fold difference of -4 indicates 4 times less expression in cancer tissue than 
in normal tissue. P-values reflect significant fold differences in expression between cancer and control tissues using the appropriate t-test; cancer types are listed in order of decreasing significance of MAO-A expression. All 
datasets showed a significant change as determined by the sequential Bonferoni-Holm adjustment unless marked § The percentage column contains the percent of individual cancer tissue samples in each data set that had lower 
levels of MAO-A expression than the lowest single control sample.BMC Genomics 2008, 9:134 http://www.biomedcentral.com/1471-2164/9/134
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expect that MAO-A-specific inhibitors may increase cancer
risk. Indeed, MAO-AIs and other antidepressants increase
cell proliferation in animal models [34-37]. If the same is
true for humans, then MAO-AI's may be particularly likely
to increase cancer risk.
SSRIs, another class of antidepressants, have recently been
shown to be effective in vitro at inducing apoptosis in
biopsy-like Burkitt's lymphoma cells, and have been
shown in vivo to reduce the risk of colon cancer [9,38]. Vis-
ual inspection of data from precancerous tissue in MMTV-
Neu and Patched heterozygote transgenic mice suggests
that there is more severe downregulation in MAO-A
expression in cancer than in the pre-cancerous condition.
This study adds to the evidence that SSRIs may be a safer
alternative than other antidepressants for treatment of
depression in patients with a precancerous condition
(such as Atypical Ductal Hyperplasia or Barrett's Esopha-
gus) or cancer [16].
Expression of MAO-A in normal and cancer tissue samples Figure 1
Expression of MAO-A in normal and cancer tissue samples. Tissues are from humans (H), mice (Mus musculus, M), rats 
(Rattus norvegicus, R), or zebrafish (Danio rerio, Z). Values are included for each dataset with independent samples in both 
human and animal models. Although all analyses were conducted on raw MAO-A expression levels, here we show both normal 
(white bars) and cancer (black bars) expression levels as a percentage of the mean expression in normal tissue within that data 
set. Control and cancer MAO-A expression levels are significantly different for all of the cancer types shown. Error bars indi-
cate standard error of the mean.BMC Genomics 2008, 9:134 http://www.biomedcentral.com/1471-2164/9/134
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Since genechips measure mRNA levels within a complex
sample we were unable to discriminate between actively
dividing cells and those at rest. It is possible the downreg-
ulation of MAO-A observed occurs in the resting cells.
Although the presence of downregulation in many can-
cers is compelling, this evidence is not adequate to estab-
lish causation, and further clinical studies are needed to
determine whether MAOIs and specifically MAO-AIs
cause an increase in cancer risk.
Conclusion
Most current cancer research is focused on tissue-specific
genetic mutations. Familial inheritance (e.g., APC in
colon cancer), genetic mutation (e.g., p53), and overex-
pression of growth receptors (e.g., Her2-neu in breast can-
cer) can each lead to aberrant replication of a cell. Studies
of these changes provide tremendous information about
tissue-specific effects but are less informative about com-
mon changes that occur in multiple tissues. The similarity
in the behavior of cancers from different organ systems
and species indicates the potential for a universal change
among cancers, regardless of the specific tissue or species.
This study suggests that downregulation of MAO-A is such
a change and could be an important indicator or even a
factor in the development and spread of many types of
cancers.
Interestingly, MAO-A inhibitors have been identified in
tobacco [39]. If decreased expression of MAO-A is demon-
strated in clinical trials to be a risk factor for development
of cancer, it may be particularly important for individuals
with low levels of MAO-A to be advised against smoking.
Future studies should investigate links between smoking,
MAO-A suppression, and the development of cancer to
determine whether MAO-A suppression might be a mech-
anism by which smoking contributes to increased cancer
risk. There are already previously published reports show-
ing that PET scans can detect decreased MAO-A levels in
smokers [40]. Our research shows that whole body PET
scans might be a non-invasive way to identify MAO-A
"cold spots", where localized downregulation indicates
increased risk of cancer at that site. This type of a marker
would permit more accurate diagnosis, leading to earlier
treatment, and improved outcomes. Clinical studies are
needed to determine whether changes in MAO-A can be
used as a prognostic indicator of cancer risk in patients
with a precancerous state.
Although the role of MAO-A in cancer has yet to be fully
understood, examination of our results suggests its expres-
sion may act as a marker for the development of cancer.
The presence of reduced expression of MAO-A in pre-can-
cerous states implies its levels indicate progression
towards cancer, suggesting that MAO-A levels can be used
to identify individuals that should receive increased sur-
veillance and testing for the potential onset of cancer.
Methods
19 Genechip datasets consisting of cancerous tissue from
10 different organs derived from human, mouse, rat or
zebrafish were extracted from the GEO profiles database.
Datasets were first identified by using the search terms
"cancer" or "metastasis". All datasets in the GEO profiles
database as of March 31st 2007 were considered. The gene-
chip data was selected such that both control and cancer
samples were contained in the same dataset. Because of
the differences in gene expression that are inherent to cell
culture and fixation [41,42], only data derived from non-
processed primary biopsies was used. By definition cancer
implies an invasive phenotype therefore all other tumor
types were excluded such as adenomas, and carcinomas in
situ. Among datasets that contained multiples types of
cancer, the cancer with the closest number of samples to
the control was used for analysis.
Table 2 describes the datasets used, which include 12
human cancer datasets, five mouse cancer datasets, one rat
cancer dataset, and one dataset from zebrafish. All animal
datasets were derived from cancers that were induced
using viral, genetic, or by chemical means. No xenografts
were included in this analysis. In total, 242 cancerous
samples and 139 control samples were used. Prior to anal-
ysis, data that was logarithmic was transformed back to its
original values, and all "null" values were excluded. Data
points that were from more then one patient, also called
pooled samples, were also excluded. Previous reports have
shown that probe-sets can not be averaged [43] therefore
all analyses were preformed on the probe-set with the
highest mean expression value. Each genechip dataset was
normalized (both intrachip and interchip) before being
deposited in the GEO database. We independently vali-
dated the normalization in every dataset by inspecting the
distribution of expression values. Datasets that were not
appropriately normalized were excluded.
As our interest was in tryptophan-related genes, we exam-
ined all human, mouse, and zebrafish tryptophan path-
way genes (~60 genes depending on the species and gene
chip) listed in Kyoto Encyclopedia of genes and genomes
(KEGG) using BRB-array tools [44] developed by the
National Cancer Institute's Biometrics Research Branch
(NCI BRB). Table 1 lists all the tryptophan genes in KEGG
and Figure 2 is a graphical representation of the tryp-
tophan genes included in this analysis, and the number of
datasets in which these genes were differentially
expressed. First, differences in the expression levels of the
genes were examined within each of the individual cancer
datasets. We performed either related samples or inde-
pendent samples t-tests (as appropriate, see Table 2) onBMC Genomics 2008, 9:134 http://www.biomedcentral.com/1471-2164/9/134
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A pathway representation of all the tryptophan related genes analyzed Figure 2
A pathway representation of all the tryptophan related genes analyzed. The figure was created by Ingenuity Pathway 
Studio, by importing the frequency of differential expression along with the gene name. The genes were then mapped and the 
frequency of differential expression was overlaid on top of the respective gene. The numbers below each gene represent the 
number of datasets in which a t-test of the gene's expression level resulted in p ≥ 0.05. The intensity of the coloration is pro-
vided to show respectively the number of datasets in which differential expression occurred. Gene names are capitalized and 
small molecules are lower case.BMC Genomics 2008, 9:134 http://www.biomedcentral.com/1471-2164/9/134
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the change in expression of the genes between control and
cancer samples for each dataset. Since we focused on the
behavior of individual genes across multiple types of can-
cer rather than groups of genes in individual datasets we
only compensated for the multiple t-tests over the com-
posite number of datasets. The probability that we would
observe the same false positive from among approxi-
mately 60 genes, in at least 16 out of the 19 separate data-
sets, is at most of the order of 7.8 × 10-17, an unlikely
outcome. Therefore finding one specific gene (MAO-A)
which is consistently down-regulated in 16 out of 19 data-
sets is an indication that the observed down-regulation of
MAO-A in cancer tissues cannot be attributed to chance
alone. Nonetheless, we did adjust for multiple t-tests
among the 19 datasets by using the Bonferroni-Holm
adjustment [45,46]. Specifically, we sorted the p-values
for t-tests of expression of each gene from smallest to larg-
est and compared the i-th p-value to the original alpha
level (0.05) divided by the number of data sets+1-i. Thus we
compared the smallest (first) p-value with 0.05/18 =
0.0028 and the largest (last) p-value with 0.05/1 = 0.05.
For each dataset a list of tryptophan related genes whose
expression level was significantly changed using these cri-
teria was generated. Then the frequency of each gene
appearing in all the lists was counted and the genes were
sorted by the frequency from high to low. Only MAO-A
was deregulated in the majority of the datasets analyzed.
Abbreviations
MOA-A, Monoamine Oxidase A; qPCR, real time
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